文献速递脑血管病

急性缺血性卒中再灌注治疗后早期复发性卒中及血栓事件风险:一项Meta分析

Risk of Early Recurrent Stroke and Thrombotic Events After Reperfusion Therapy in Acute Ischemic Stroke: A Meta-Analysis.
PubMed 文献 · Stroke · 2025-10-20

该Meta分析纳入15项RCT(n=4898)比较血管内取栓与最佳药物治疗,9项RCT(n=7193)比较静脉溶栓与最佳药物治疗,评估90天内早期复发性卒中和非卒中血栓事件风险。结果显示再灌注治疗未增加早期复发性卒中或非卒中血栓事件风险。

要点

  • 血管内取栓与最佳药物治疗相比,早期复发性卒中风险无显著差异(RR 1.2,95%CI 0.9-1.6)。
  • 静脉溶栓与最佳药物治疗相比,早期复发性卒中风险无显著差异(RR 1.1,95%CI 0.8-1.5)。

核心结论

  • 急性缺血性卒中发病24小时内行再灌注治疗(血管内取栓±静脉溶栓)与最佳药物治疗相比,不增加90天内复发性卒中或非卒中血栓事件风险。

研究设计与样本

  • 本研究为Meta分析,纳入15项RCT(n=4898)比较血管内取栓与最佳药物治疗,9项RCT(n=7193)比较静脉溶栓与最佳药物治疗,另14项RCT(n=4033)和5项RCT(n=4961)分别报告非卒中血栓事件。

主要发现

  • 血管内取栓组早期复发性卒中发生率为5.5%(143/2618),最佳药物治疗组为4.5%(102/2280),RR 1.2(95%CI 0.9-1.6)。
  • 静脉溶栓组早期复发性卒中发生率为2%(73/3615),最佳药物治疗组为1.8%(66/3578),RR 1.1(95%CI 0.8-1.5)。
  • 静脉溶栓组非卒中血栓事件发生率为2%(51/2479),最佳药物治疗组为2.2%(54/2482),RR 0.9(95%CI 0.6-1.4)。

临床怎么用

  • 对于急性缺血性卒中发病24小时内的患者,再灌注治疗不增加早期复发性卒中及非卒中血栓事件风险,临床决策时可据此权衡获益与风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Following an acute ischemic stroke, the risk of recurrent stroke is highest in the first 90 days. It is unclear whether this risk is altered by reperfusion therapy. In this meta-analysis, we aim to evaluate the risk of early recurrent stroke and other nonstroke thrombotic events postreperfusion therapy in acute ischemic stroke. METHODS: In this meta-analysis, randomized controlled trials (RCTs) were included in adults aged 18 years or older with acute ischemic stroke, comparing reperfusion treatment with best medical management (MED). We searched PUBMED, Embase, Cochrane Library, and Web of Science databases. The studies were grouped into endovascular thrombectomy (EVT) versus MED and intravenous thrombolysis versus MED. We performed a meta-analysis using a random-effects model (restricted maximum likelihood) to estimate the log risk ratio (RR) of early recurrent stroke and nonstroke thrombotic events (NSTE)-including myocardial infarction, acute coronary syndrome, deep vein thrombosis, pulmonary embolism, and peripheral embolism-after reperfusion therapy compared with MED at 90 days after symptom onset. This study is registered with PROSPERO (The International Prospective Register of Systematic Reviews). RESULTS: A total of 15 RCTs (n=4898) comparing EVT versus MED observed no difference in early recurrent stroke (5.5%, 143/2618 versus 4.5%, 102/2280; RR, 1.2 [95% CI, 0.9-1.6]). Nine RCTs (n=7193) comparing intravenous thrombolysis versus MED observed no difference in early recurrent stroke (2%, 73/3615 versus 1.8%, 66/3578; RR, 1.1 [95% CI, 0.8-1.5]). Fourteen RCTs (n=4033) comparing EVT versus MED reported NSTE. There was no difference in NSTE in the EVT arm (3.1%, 62/2024 versus 3.1%, 62/2009; RR, 1 [95% CI, 0.7-1.4]). Five RCTs (n=4961) comparing intravenous thrombolysis versus MED observed no difference in NSTE (2%, 51/2479 versus 2.2%, 54/2482; RR, 0.9 [95% CI, 0.6-1.4]). CONCLUSIONS: Reperfusion therapies (EVT±intravenous thrombolysis) in acute ischemic stroke within 24 hours of symptom onset were not associated with increased recurrent stroke or NSTE within 90 days compared with best medical therapy. REGISTRATION: URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42024542020.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Ashayeri Ahmadabad R, Sobchuk K, Cheema SK, et al. Risk of Early Recurrent Stroke and Thrombotic Events After Reperfusion Therapy in Acute Ischemic Stroke: A Meta-Analysis. Stroke. 2025. PMID: 41111409. doi:10.1161/STROKEAHA.125.050672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。